「」至此。关于航天器部件，请见「**锚钩固定装置**」。

**血小板衍生生長因子**（Platelet-derived growth factor，PDGF）為一種生長因子，可以調控細胞的生長和分化，且在血管新生上扮演重要角色。未控制的血管新生常常導致癌症。在化學上PDGF為醣蛋白二聚體，且有A和B兩種不同形式，可組合為AA、AB和BB等結構。

PDGF是一種有效的间充质細胞丝裂原，包含纖維母細胞、平滑肌、神經膠細胞。在小鼠和人类中，PDGF信号网络都包括四種配体：PDGFA 到 PDGFAD，与两个受体:PDGFRA和PDGFRB。所有PDGF都表达到胞外，并通过二硫键连接形成同元二聚体，但只有PDGFA和B可以形成有功能的异元二聚体。

PDGF在被合成出來之後，會先貯存在血小板中的α顆粒當中，直到受到刺激後才釋放出來。另外，平滑肌細胞、活化的巨噬細胞，和上皮細胞等多種細胞也會製造PDGF。

醫療上，可使用合成PDGF加速慢性潰瘍病灶的癒合；骨科和牙周病專科上也會以PDGF治療骨質流失。

分類
--

PDGF擁有五種亞型（英语：）

已隱藏部分未翻譯内容，歡迎參與翻譯。
There are five different isoforms of PDGF that activate cellular response through two different receptors. Known ligands include A (*PDGFA*), B (*PDGFB*), C (*PDGFC*), and D (*PDGFD*), and an AB heterodimer and receptors alpha (*PDGFRA*) and beta (*PDGFRB*). PDGF has few other members of the family, for example VEGF sub-family.

機制
--

The receptor for PDGF, **PDGFR** is classified as a receptor tyrosine kinase (RTK), a type of cell surface receptor. Two types of PDGFRs have been identified: alpha-type and beta-type PDGFRs. The alpha type binds to PDGF-AA, PDGF-BB and PDGF-AB, whereas the beta type PDGFR binds with high affinity to PDGF-BB and PDGF-AB.
PDGF binds to the PDGFR ligand binding pocket located within the second and third immunoglobulin domains. Upon activation by PDGF, these receptors dimerise, and are "switched on" by auto-phosphorylation of several sites on their cytosolic domains, which serve to mediate binding of cofactors and subsequently activate signal transduction, for example, through the PI3K pathway or through reactive oxygen species (ROS)-mediated activation of the STAT3 pathway. Downstream effects of this include regulation of gene expression and the cell cycle.
The role of PI3K has been investigated by several laboratories. Accumulating data suggests that, while this molecule is, in general, part of growth signaling complex, it plays a more profound role in controlling cell migration.
The different ligand isoforms have variable affinities for the receptor isoforms, and the receptor isoforms may variably form hetero- or homo- dimers. This leads to specificity of downstream signaling. It has been shown that the *sis* oncogene is derived from the PDGF B-chain gene. PDGF-BB is the highest-affinity ligand for the PDGFR-beta; PDGFR-beta is a key marker of hepatic stellate cell activation in the process of fibrogenesis.[來源請求]

功能
--

PDGFs are mitogenic during early developmental stages, driving the proliferation of undifferentiated mesenchyme and some progenitor populations. During later maturation stages, PDGF signalling has been implicated in tissue remodelling and cellular differentiation, and in inductive events involved in patterning and morphogenesis. In addition to driving mesenchymal proliferation, PDGFs have been shown to direct the migration, differentiation and function of a variety of specialised mesenchymal and migratory cell types, both during development and in the adult animal. Other growth factors in this family include vascular endothelial growth factors B and C (VEGF-B, VEGF-C) which are active in angiogenesis and endothelial cell growth, and placenta growth factor (PlGF) which is also active in angiogenesis.

PDGF plays a role in embryonic development, cell proliferation, cell migration, and angiogenesis. Over-expression of PDGF has been linked to several diseases such as atherosclerosis, fibrotic disorders and malignancies. Synthesis occurs due to external stimuli such as thrombin, low oxygen tension, or other cytokines and growth factors.

PDGF is a required element in cellular division for fibroblasts, a type of connective tissue cell that is especially prevalent in wound healing. In essence, the PDGFs allow a cell to skip the G1 checkpoints in order to divide. It has been shown that in monocytes-macrophages and fibroblasts, exogenously administered PDGF stimulates chemotaxis, proliferation, and gene expression and significantly augmented the influx of inflammatory cells and fibroblasts, accelerating extracellular matrix and collagen formation and thus reducing the time for the healing process to occur.

In terms of osteogenic differentiation of mesenchymal stem cells, comparing PDGF to epidermal growth factor (EGF), which is also implicated in stimulating cell growth, proliferation, and differentiation, MSCs were shown to have stronger osteogenic differentiation into bone-forming cells when stimulated by epidermal growth factor (EGF) versus PDGF. However, comparing the signaling pathways between them reveals that the PI3K pathway is exclusively activated by PDGF, with EGF having no effect. Chemically inhibiting the PI3K pathway in PDGF-stimulated cells negates the differential effect between the two growth factors, and actually gives PDGF an edge in osteogenic differentiation. Wortmannin is a PI3K-specific inhibitor, and treatment of cells with Wortmannin in combination with PDGF resulted in enhanced osteoblast differentiation compared to just PDGF alone, as well as compared to EGF. These results indicate that the addition of Wortmannin can significantly increase the response of cells into an osteogenic lineage in the presence of PDGF, and thus might reduce the need for higher concentrations of PDGF or other growth factors, making PDGF a more viable growth factor for osteogenic differentiation than other, more expensive growth factors currently used in the field such as BMP2.

PDGF is also known to maintain proliferation of oligodendrocyte progenitor cells. It has also been shown that fibroblast growth factor (FGF) activates a signaling pathway that positively regulates the PDGF receptors in oligodendrocyte progenitor cells.

歷史
--

PDGF是第一种被鉴定的生长因子，引领了许多生长因子信号通路的研究[來源請求]。

藥物
--

Recombinant PDGF is used to help heal chronic ulcers and in orthopedic surgery and periodontistry to treat bone loss.

研究
--

Like many other growth factors that have been linked to disease, PDGF and its receptors have provided a market for receptor antagonists to treat disease. Such antagonists include (but are not limited to) specific antibodies that target the molecule of interest, which act only in a neutralizing manner.

The "c-Sis" oncogene is derived from PDGF.

Age related downregulation of the PDGF receptor on islet beta cells has been demonstrated to prevent islet beta cell proliferation in both animal and human cells and its re-expression triggered beta cell proliferation and corrected glucose regulation via insulin secretion.

A non-viral PDGF "bio patch" can regenerate missing or damaged bone by delivering DNA in a nano-sized particle directly into cells via genes. Repairing bone fractures, fixing craniofacial defects and improving dental implants are among potential uses. The patch employs a collagen platform seeded with particles containing the genes needed for producing bone. In experiments, it new bone fully covered skull wounds in test animals and stimulated growth in human bone marrow stromal cells.

PDGF家族
------

Human genes encoding proteins that belong to the platelet-derived growth factor family include:

* FIGF
* PDGFA; PDGFB; PDGFC; PDGFD
* PGF
* VEGF; VEGF41; VEGFB; VEGFC;

參見
--

* Platelet-activating factor
* Platelet-derived growth factor receptor
* atheroma platelet involvement in smooth muscle proliferation
* Withaferin A potent inhibitor of angiogenesis

參考文獻
----

1. ↑  Hannink M, Donoghue DJ.. Biochim. Biophys. Acta. 1989, **989** (1): 1–10. PMID 2546599. doi:10.1016/0304-419x(89)90031-0.
2. ↑  Heldin CH.. EMBO J. 1992, **11** (12): 4251–4259. PMC 556997 可免费查阅. PMID 1425569.
3. ↑ .  [2014-05-08]. （原始内容存档于2018-10-02）.
4. ↑  Kumar, Vinay.. China: Elsevier. 2010: 88–89. ISBN 978-1-4160-3121-5.
5. ↑  Matsui T, Heidaran M, Miki T, Popescu N, La Rochelle W, Kraus M, Pierce J, Aaronson S.. Science. 1989, **243** (4892): 800–4. PMID 2536956. doi:10.1126/science.2536956.
6. ↑  Heidaran MA, Pierce JH, Yu JC, Lombardi D, Artrip JE, Fleming TP, Thomason A, Aaronson SA.. J. Biol. Chem. 25 October 1991, **266** (30): 20232–7  [2015-05-24]. PMID 1657917. （原始内容存档于2008-11-05）.
7. ↑  Heidaran MA, Pierce JH, Jensen RA, Matsui T, Aaronson SA.. J. Biol. Chem. 5 November 1990, **265** (31): 18741–4  [2015-05-24]. PMID 2172231. （原始内容存档于2008-07-25）.
8. ↑  Blazevic T, Schwaiberger AV, Schreiner CE, Schachner D, Schaible AM, Grojer CS, Atanasov AG, Werz O, Dirsch VM, Heiss EH.. J. Biol. Chem. December 2013, **288** (49): 35592–603. PMC 3853304 可免费查阅. PMID 24165129. doi:10.1074/jbc.M113.489013.
9. ↑  Yu JC, Li W, Wang LM, Uren A, Pierce JH, Heidaran MA.. J. Biol. Chem. 1995, **270** (13): 7033–6. PMID 7706238. doi:10.1074/jbc.270.13.7033.
10. ↑  Hoch RV, Soriano P.. Development. 2003, **130** (20): 4769–4784. PMID 12952899. doi:10.1242/dev.00721.
11. ↑  Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U.. Proc. Natl. Acad. Sci. U.S.A. 1996, **93** (6): 2567–2581. PMC 39839 可免费查阅. PMID 8637916. doi:10.1073/pnas.93.6.2576.
12. ↑  Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K.. EMBO J. 1996, **15** (2): 290–298. PMC 449944 可免费查阅. PMID 8617204.
13. ↑  Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY, Persico MG.. Oncogene. 1993, **8** (4): 925–931. PMID 7681160.
14. ↑ .  [2007-11-17]. （原始内容存档于2006-11-13）.
15. 1 2  Alvarez RH, Kantarjian HM, Cortes JE.. Mayo Clin. Proc. September 2006, **81** (9): 1241–57. PMID 16970222. doi:10.4065/81.9.1241.
16. ↑  Song G, Ouyang G, Bao S.. J. Cell. Mol. Med. 2005, **9** (1): 59–71. PMID 15784165. doi:10.1111/j.1582-4934.2005.tb00337.x.
17. ↑  Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A.. J. Cell. Biochem. April 1991, **45** (4): 319–26. PMID 2045423. doi:10.1002/jcb.240450403.
18. 1 2 3  Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M.. Science. June 2005, **308** (5727): 1472–7. PMID 15933201. doi:10.1126/science.1107627.
19. ↑  Hayashi, A. The New Standard of Care for Nonunions?. AAOS Now. 2009.
20. ↑  Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, Raff MC.. Cell. 1992, **70** (1): 31–46. PMID 1623522. doi:10.1016/0092-8674(92)90531-G.
21. 1 2  醫學主題詞表（MeSH）：*Proto-Oncogene+Proteins+c-sis*
22. ↑  McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA.. Neuron. November 1990, **5** (5): 603–14. PMID 2171589. doi:10.1016/0896-6273(90)90215-2.
23. ↑  Paul D, Lipton A, Klinger I.. Proc Natl Acad Sci U S A. 1971, **68** (3): 645–52. PMC 389008 可免费查阅. PMID 5276775. doi:10.1073/pnas.68.3.645.
24. ↑  Friedlaender GE et al. The Role of Recombinant Human Platelet-derived Growth Factor-BB (rhPDGF-BB) in Orthopaedic Bone Repair and Regeneration Curr Pharm Des. 2013;19(19):3384-90. PMID 23432673. Quote: "Demonstration of the safety and efficacy of rhPDGF-BB in the healing of chronic foot ulcers in diabetic patients and regeneration of alveolar (jaw) bone lost due to chronic infection from periodontal disease has resulted in two FDA-approved products based on this molecule"
25. ↑  Shulman T, Sauer FG, Jackman RM, Chang CN, Landolfi NF.. J. Biol. Chem. July 1997, **272** (28): 17400–4. PMID 9211881. doi:10.1074/jbc.272.28.17400.
26. ↑  McClintock JT, Chan IJ, Thaker SR, Katial A, Taub FE, Aotaki-Keen AE, Hjelmeland LM.. In Vitro Cell Dev Biol. 1992, **28A** (2): 102–8. PMID 1537750. doi:10.1007/BF02631013.
27. ↑ . Eurekalert.org. 2011-10-12  [2013-12-28]. （原始内容存档于2018-12-12）.
28. ↑ . Med.stanford.edu. 2011-10-12  [2013-12-28]. （原始内容存档于2013-10-21）.
29. ↑ . KurzweilAI. 2013-11-12  [2013-12-28]. doi:10.1016/j.biomaterials.2013.10.021. （原始内容存档于2021-01-26）.
30. ↑  Elangovan S, D'Mello SR, Hong L, Ross RD, Allamargot C, Dawson DV, Stanford CM, Johnson GK, Sumner DR, Salem AK.. Biomaterials. 2014, **35** (2): 737–747. PMC 3855224 可免费查阅. PMID 24161167. doi:10.1016/j.biomaterials.2013.10.021.

外部連結
----

* 醫學主題詞表（MeSH）：*platelet-derived+growth+factor*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 

| * 
* 论
* 编
生长因子 |
| --- |
|  |
| 成纤维细胞生长因子（**FGF**） | 

|  |  |
| --- | --- |
| 成纤维细胞生长因子受体（FGFR）配体 | FGF1/FGF2/FGF5 · FGF3/FGF4/FGF6 |
|  |
| 角质细胞生长因子（英语：）（KGF） | FGF7/FGF10/FGF22 · FGF8/FGF17/FGF18 · FGF9/FGF16/FGF20 |
|  |
| FGF同源生长因子（FHF） | FGF11 · FGF12 · FGF13 · FGF14 |
|  |
| 激素样FGF | FGF19 · FGF21 · FGF23 |

 |
|  |
| EGF-like domain | 转化生长因子-α · 表皮生长因子  · HB-EGF |
|  |
| TGF-β信号通路（英语：） | 转化生长因子-β (转化生长因子-β1, 转化生长因子-β2, 转化生长因子-β3) |
|  |
| 胰岛素样生长因子 | IGF-1 · IGF-2（英语：） |
|  |
| 血小板衍生生长因子 | PDGFA · PDGFB · PDGFC · PDGFD |
|  |
| 血管内皮生长因子 | VEGF-A · VEGF-B · VEGF-C · VEGF-D · PGF |
|  |
| 其它 | 神经生长因子（英语：） · 肝细胞生长因子（英语：） |
|  |
| 

|  信号转导索引 |
| --- |
|  |
| 描述 | 
* 胞外
	+ 神經肽
	+ 生长因子
	+ 细胞因子
	+ 激素
* 細胞表面受體（英语：）
	+ 配体门控离子通道
	+ 酶联受體
	+ G蛋白偶聯受體
	+ 免疫球蛋白超家族（英语：）
	+ 整合素
	+ 神經肽受體
	+ 生長因子受體
	+ 细胞因子受體
* 胞內
	+ 受體蛋白（英语：）
	+ GTP-binding（英语：）
	+ MAP激酶
* 鈣信號
* 脂質系號
* 路徑
	+ hedgehog
	+ Wnt
	+ TGF-β
	+ MAPK ERK（英语：）
	+ notch（英语：）
	+ JAK-STAT
	+ 細胞凋亡
	+ hippo（英语：）
	+ TLR

 |

 |

 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 

| * 
* 论
* 编
新生物：肿瘤抑制基因/蛋白与癌基因/原癌基因 |
| --- |
|  |
| 配體 | 

|  |  |
| --- | --- |
| 生长因子 | 
* ONCO：c-Sis/PDGF
* HGF

 |

 |
|  |
| 受体 | 

|  |  |
| --- | --- |
| Wnt信号通路 | 
* TSP: CDH1

 |
|  |
| 刺猬信号通路 | 
* TSP：PTCH1

 |
|  |
| TGFβ信号通路 | 
* TSP: TGFβ受体2

 |
|  |
| 受体酪氨酸激酶 | 
* ONCO: ErbB/c-ErbB
	+ HER2/neu
	+ Her 3
* c-Met
* c-Ret

 |
|  |
| JAK-STAT信号通路 | 
* ONCO：c-Kit
* Flt3

 |

 |
|  |
| 胞内信号P+P | 

|  |  |
| --- | --- |
| Wnt信号通路 | 
* ONCO：β-联蛋白
* TSP：APC

 |
|  |
| TGFβ信号通路 | 
* TSP：SMAD2
* SMAD4

 |
|  |
| Akt/PKB信号通路 | 
* TSP：PTEN
* ONCO：c-Akt

 |
|  |
| 河马信号通路 | TSP：神经纤维瘤蛋白2/膜突样蛋白 |
|  |
| MAPK/ERK途径 | 
* TSP：神经纤维瘤蛋白1
* ONCO：c-Ras
* HRAS
* c-Raf

 |
|  |
| 其他/未知 | 
* TSP: Maspin
* ONCO: c-Src

 |

 |
|  |
| 核 | 

|  |  |
| --- | --- |
| 细胞周期 | 
* TSP：p53
* pRb
* WT1
* p16/p14arf
* ONCO：CDK4
* 周期蛋白D
* 周期蛋白E

 |
|  |
| DNA修复/范科尼 | 
* TSP：BRCA1
* BRCA2

 |
|  |
| 泛素连接酶 | 
* TSP：VHL
* ONCO: CBL
* MDM2

 |
|  |
| 转录因子 | 
* TSP: KLF6
* ONCO: AP-1
	+ c-Fos
	+ c-Jun
* c-Myc

 |

 |
|  |
| 线粒体 | 
* 凋亡抑制剂：SDHB
* SDHD

 |
|  |
| 其他/未分组 | 
* c-Bcl-2 - Notch - 抑微管装配蛋白

 |
|  |
| 

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 

|  |  |  |  |
| --- | --- | --- | --- |
| 
医学导航: 肿瘤
 | 
基因/标志
 | 
肿瘤/同名/附瘤
 | 
药物 (L1i/1e/V03)
 |

 |

 |

 |